Key facts
- Advanced NanoTherapies secured over $31 million in Series B funding.
- The funding will support U.S. Investigational Device Exemption (IDE) approval.
- Funds will advance coronary clinical trials.
- Financing will support expansion into below-the-knee peripheral (BTK) applications.
- ANT's platform uses a dual-drug (Paclitaxel and Sirolimus) nanoparticle-coated balloon.
Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech company, has successfully raised over $31 million in Series B financing. This funding is earmarked to support the company's efforts in obtaining U.S. Investigational Device Exemption (IDE) approval, advancing its coronary clinical trials, and expanding its innovative dual-drug nanoparticle-coated balloon platform into below-the-knee peripheral (BTK) applications. The platform utilizes a combination of Paclitaxel and Sirolimus for vascular treatment.